InvestorsHub Logo
Followers 23
Posts 2120
Boards Moderated 0
Alias Born 06/21/2015

Re: hessmessinc post# 121095

Thursday, 09/21/2017 7:24:03 AM

Thursday, September 21, 2017 7:24:03 AM

Post# of 461572

ANAVEX™ 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.



This is not vague.

This would be a perfect venue to announce the start of the multiple CNS trials. Of course it would be PRed before the event... JMO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News